Drugs / lirentelimab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04324268 | Mar 2020 → Feb 2021 | — | Allakos Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03379311 | Feb 2018 → Aug 2019 | atopic keratoconjunctivitis, conjunctivitis, vernal keratoconjunctivitis | Allakos Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02859701 | Aug 2016 → May 2017 | — | Allakos Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02808793 | Jun 2016 → Dec 2018 | indolent systemic mastocytosis | Allakos Inc. | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT05528861 | Oct 2022 → Dec 2023 | chronic urticaria | Allakos Inc. | Terminated | Missed primary |
| Phase 2 | NCT05155085 | Jun 2022 → Dec 2023 | atopic eczema | Allakos Inc. | Terminated | Missed primary |
| Phase 2 | NCT03664960 | Nov 2018 → Nov 2021 | eosinophilic gastritis | Allakos Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03496571 | Jul 2018 → Jun 2019 | eosinophilic gastritis | Allakos Inc. | Completed | Met primary |
| Phase 2 | NCT03436797 | Jan → Nov 2018 | chronic urticaria | Allakos Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04322708 | Jul 2020 → Jun 2021 | eosinophilic esophagitis | Allakos Inc. | Completed | Mixed |
| Phase 34 trials | ||||||
| Phase 3 | NCT05152563 | Dec 2021 → Jan 2022 | eosinophilic gastritis | Allakos Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04856891 | May 2021 → Jun 2022 | eosinophilic gastroenteritis | Allakos Inc. | Completed | Mixed |
| Phase 3 | NCT04620811 | Dec 2020 → May 2023 | eosinophilic gastritis | Allakos Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04322604 | Jun 2020 → Nov 2021 | eosinophilic gastritis | Allakos Inc. | Completed | Mixed |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lirentelimab | “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous...” NCT05152563 ↗6“AK002 (lirentelimab) is an anti-Siglec-8 antibody that depletes eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for...” PMID 33085861 ↗ Oct 2020 |
| Known as | AK002 | “Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.” NCT04322604 ↗12“Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8” NCT04620811 ↗ “Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.” NCT04324268 ↗ “Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).” NCT04322708 ↗ |
| Known as | Antolimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297878 ↗ |
| Known as | Monoclonal antibody ak002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297878 ↗ |
| Action | Deplete | “AK002 (lirentelimab) is an anti-Siglec-8 antibody that depletes eosinophils and inhibits mast cells” PMID 33085861 ↗ Oct 2020 |
| Modality | Monoclonal antibody | “humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody” NCT03379311 ↗ |
| Route | Intravenous | “IV dose of AK002” NCT02808793 ↗ |
| Target | SIGLEC8 | “AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8” NCT03496571 ↗ |